Q2 Earnings Beats: Caterpillar Posts $7.77 EPS on $20 Billion Revenue Leading 10-Company Industrial and Consumer Surge

The Quick Take

• Caterpillar posts Q2 EPS of $7.77 on $20 billion revenue, beating estimates and reinforcing global construction demand strength
• Harmony Biosciences reports Q2 revenue surge of 30% year-over-year at $261 million, validating rare neurological therapy growth
• LGI Homes, Knife River, Ball Corp, and Kimberly-Clark also beat estimates in a broadly positive 10-company Q2 cluster

A ten-company Q2 earnings cluster delivered a predominantly positive result, anchored by Caterpillar's standout beat of EPS $7.77 on $20 billion in revenue. Caterpillar's result is a leading indicator for global construction, mining, and infrastructure activity — the kind of number that signals continued strength in both North American and international project pipelines. Harmony Biosciences also impressed with a 30% year-over-year revenue surge to $261 million in its rare neurological therapy business, demonstrating that specialty pharma companies with strong patent-protected drug portfolios can deliver high-growth compounding even in a cost-constrained healthcare environment.

LGI Homes reported EPS of $1.16 on $516 million in revenue, beating estimates — a result that challenges the narrative of a slowing housing market and suggests that entry-level homebuilders serving affordable price points continue to find demand. Knife River Corporation beat at $0.77 EPS on $938 million revenue; Ball Corporation delivered $0.83 EPS on over $3 billion revenue; Hillman Solutions beat at $0.11 EPS on $442 million revenue; Kimberly-Clark reported $1.80 EPS on $4 billion revenue above estimates. Westlake Corp and TPG also reported, with Westlake showing significant profitability recovery. Graphic Packaging missed at $0.08 EPS, with $2 billion revenue below consensus.

The overwhelmingly positive tone of this ten-company cluster — nine beats against one miss — reflects a broader improvement in US industrial, consumer staples, and financial services earnings quality in Q2 2026. Caterpillar's result, in particular, will shape sentiment for the construction equipment and industrial machinery sector into Q3. Investors should watch whether CAT's Q3 guidance sustains the $20 billion revenue run rate, as any deceleration would signal global capex fatigue. Harmony Biosciences' 30% growth rate is the standout growth story; the key forward question is pipeline depth for new neurological indications. KMB's dividend trajectory and WLK's margin recovery are the primary metrics for the income and cyclical recovery cohort.

Synthesized from 10 sources.